Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1990 May;29(5):503–509. doi: 10.1111/j.1365-2125.1990.tb03672.x

Influence of acetylator status on the haemodynamic effects and pharmacokinetics of cadralazine in healthy subjects.

P Brunel 1, J B Lecaillon 1, T T Guyene 1, P Imhof 1, J Ménard 1
PMCID: PMC1380148  PMID: 2190629

Abstract

1. Cadralazine is a new antihypertensive agent which causes peripheral vasodilation, probably mediated by a hydrazinopyridazine metabolite. 2. The possible influence of acetylator status on the pharmacokinetics and haemodynamics of the drug was studied in six fast and six slow acetylators over a period of 24 h after administration of a single 10 mg oral dose. 3. There were no differences between the two groups in AUC and Cmax values of cadralazine and apparent metabolite, the latter defined as the sum of the free and conjugated hydrazinopyridazine. Peak plasma concentrations of these compounds were reached after 1 h. Thereafter, the concentration of the metabolite declined more slowly than that of cadralazine. 4. No effects on blood pressure were noted. Changes in heart rate and plasma renin were delayed by 3-5 h with respect to the time-course of drug and metabolite in plasma; maximum responses occurred at 4-6 h after drug administration. The extent of the increase in plasma renin activity was slightly greater in slow than in fast acetylators, but the difference was not significant statistically.

Full text

PDF
503

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bellet M., Sassano P., Guyenne T., Corvol P., Menard J. Converting-enzyme inhibition buffers the counter-regulatory response to acute administration of nicardipine. Br J Clin Pharmacol. 1987 Oct;24(4):465–472. doi: 10.1111/j.1365-2125.1987.tb03199.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Buell J. C. A practical, cost-effective, noninvasive system for cardiac output and hemodynamic analysis. Am Heart J. 1988 Aug;116(2 Pt 2):657–664. doi: 10.1016/0002-8703(88)90566-2. [DOI] [PubMed] [Google Scholar]
  3. Degen P. H., Brechbühler S., Schneider W., Zbinden P. Determination of apparent dihydralazine in plasma by gas--liquid chromatography and electron-capture detection. J Chromatogr. 1982 Dec 10;233:375–380. doi: 10.1016/s0378-4347(00)81771-5. [DOI] [PubMed] [Google Scholar]
  4. Hauffe S. A., Dubois J. P. Determination of cadralazine in human plasma and urine by high-performance liquid chromatography. J Chromatogr. 1984 May 4;290:223–230. doi: 10.1016/s0021-9673(01)93577-0. [DOI] [PubMed] [Google Scholar]
  5. Kubicek W. G., Karnegis J. N., Patterson R. P., Witsoe D. A., Mattson R. H. Development and evaluation of an impedance cardiac output system. Aerosp Med. 1966 Dec;37(12):1208–1212. [PubMed] [Google Scholar]
  6. Laurent S., Lacolley P., London G., Safar M. Hemodynamics of the carotid artery after vasodilation in essential hypertension. Hypertension. 1988 Feb;11(2):134–140. doi: 10.1161/01.hyp.11.2.134. [DOI] [PubMed] [Google Scholar]
  7. Murphy M. B., Scriven A. J., Brown M. J., Causon R., Dollery C. T. The effects of nifedipine and hydralazine induced hypotension on sympathetic activity. Eur J Clin Pharmacol. 1982;23(6):479–482. doi: 10.1007/BF00637492. [DOI] [PubMed] [Google Scholar]
  8. Ménard J., Guyenne T. T., Corvol P., Pau B., Simon D., Roncucci R. Direct immunometric assay of active renin in human plasma. J Hypertens Suppl. 1985 Dec;3(3):S275–S278. [PubMed] [Google Scholar]
  9. Reece P. A., Cozamanis I., Zacest R. Kinetics of hydralazine and its main metabolites in slow and fast acetylators. Clin Pharmacol Ther. 1980 Dec;28(6):769–778. doi: 10.1038/clpt.1980.234. [DOI] [PubMed] [Google Scholar]
  10. Safar M. E., Peronneau P. A., Levenson J. A., Toto-Moukouo J. A., Simon A. C. Pulsed Doppler: diameter, blood flow velocity and volumic flow of the brachial artery in sustained essential hypertension. Circulation. 1981 Feb;63(2):393–400. doi: 10.1161/01.cir.63.2.393. [DOI] [PubMed] [Google Scholar]
  11. Salvadeo A., Villa G., Segagni S., Piazza V., Picardi L., Romano M., Parini J. Cadralazine, a new vasodilator, in addition to a beta-blocker for long-term treatment of hypertension. Arzneimittelforschung. 1985;35(3):623–625. [PubMed] [Google Scholar]
  12. Schmid K., Küng W., Riess W., Dollery C. T., Harland S. J. Metabolism of hydralazine in man. Investigation of features relevant to drug safety, Part I. Arzneimittelforschung. 1981;31(7):1143–1147. [PubMed] [Google Scholar]
  13. Schütz H., Faigle J. W., Küng W., Theobald W. Disposition and pharmacokinetics of cadralazine and individual metabolites in man. Eur J Drug Metab Pharmacokinet. 1985 Apr-Jun;10(2):147–153. doi: 10.1007/BF03189709. [DOI] [PubMed] [Google Scholar]
  14. Silas J. H., Barker A. T., Ramsay L. E. Clinical evaluation of Dinamap 845 automated blood pressure recorder. Br Heart J. 1980 Feb;43(2):202–205. doi: 10.1136/hrt.43.2.202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Terauchi Y., Watari S., Ishikawa S., Takeyama K., Sekine Y., Hashimoto M., Hayashi T. Pharmacokinetics of an active cadralazine metabolite in plasma and blood vessels of spontaneously hypertensive rats. Arzneimittelforschung. 1988 Feb;38(2):237–239. [PubMed] [Google Scholar]
  16. Thuillez C., Gueret M., Duhaze P., Lhoste F., Kiechel J. R., Giudicelli J. F. Nicardipine: pharmacokinetics and effects on carotid and brachial blood flows in normal volunteers. Br J Clin Pharmacol. 1984 Dec;18(6):837–847. doi: 10.1111/j.1365-2125.1984.tb02553.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Timbrell J. A., Harland S. J. Identification and quantitation of hydrazine in the urine of patients treated with hydralazine. Clin Pharmacol Ther. 1979 Jul;26(1):81–88. doi: 10.1002/cpt197926181. [DOI] [PubMed] [Google Scholar]
  18. Weissler A. M., Harris W. S., Schoenfeld C. D. Systolic time intervals in heart failure in man. Circulation. 1968 Feb;37(2):149–159. doi: 10.1161/01.cir.37.2.149. [DOI] [PubMed] [Google Scholar]
  19. Zacest R., Koch-Weser J. Relation of hydralazine plasma concentration to dosage and hypotensive action. Clin Pharmacol Ther. 1972 May-Jun;13(3):420–425. doi: 10.1002/cpt1972133420. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES